Etoh T
Nihon Geka Gakkai Zasshi. 1984 Dec;85(12):1579-85.
The tumor directed cell mediated response in patients with neuroblastoma was studied in vitro by the 51Cr release cytotoxicity assay. The following results were obtained. In peripheral blood lymphocytes of disease-free and postoperative neuroblastoma patients, cytotoxic T lymphocytes (CTL) were induced in vitro against allogeneic human neuroblastoma cell (NB GOTO). Their % specific 51Cr releases were from 15.2 +/- 0.1 to 35.8 +/- 0.6&, and in some of them, specific cytotoxic activity for C-1300 murine neuroblastoma were shown (12.0 +/- 1.1%). But, nobody could be detected from patients of neuroblastoma who were preoperative or receiving chemo-radiotherapy, and as well in the control patients and other patients who had malignant tumors. Surprisingly, in Stage IV-S neuroblastoma patient, a high level of CTL appeared every time, even in the preoperative period (33.0 +/- 0.2%). The conclusion is that a clear cross activity exists in T cells mediated cytotoxic reaction between the mouse and human neuroblastoma without recognizing both major histocompatibility (MHC) determinants. Neuroblastoma cells carry specific antigenic determinants shared with both mouse and human species, that is, neuroblastoma-specific antigens have common antigenic moieties in different animal species.
通过51Cr释放细胞毒性试验在体外研究了神经母细胞瘤患者的肿瘤定向细胞介导反应。得到了以下结果。在无病和术后神经母细胞瘤患者的外周血淋巴细胞中,体外诱导出针对同种异体人神经母细胞瘤细胞(NB GOTO)的细胞毒性T淋巴细胞(CTL)。它们的特异性51Cr释放率为15.2±0.1%至35.8±0.6%,其中一些对C-1300小鼠神经母细胞瘤显示出特异性细胞毒性活性(12.0±1.1%)。但是,在术前或接受放化疗的神经母细胞瘤患者以及对照患者和其他患有恶性肿瘤的患者中均未检测到CTL。令人惊讶的是,在IV-S期神经母细胞瘤患者中,即使在术前阶段,每次都出现高水平的CTL(33.0±0.2%)。结论是,在小鼠和人神经母细胞瘤之间的T细胞介导的细胞毒性反应中存在明显的交叉活性,而无需识别主要组织相容性(MHC)决定簇。神经母细胞瘤细胞携带与小鼠和人类共有的特异性抗原决定簇,即神经母细胞瘤特异性抗原在不同动物物种中具有共同的抗原部分。